Lab test could match cancer patients to the right drugs
NCT ID NCT07468422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by their doctor. The goal is to see if OPTin-guided therapy improves tumor shrinkage and overall health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The patients will receive treatments in CMUH.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults aged 18 years or older. 2. Willing to sign the informed consent form prior to any study-related procedures. 3. Histologically confirmed participants with metastatic or advanced solid tumor that is not curable with local therapies. 4. Able to provide a tissue specimen larger than \[(0.5 cm)³\] via surgery during the screening period. 5. Willing to allow the use of their previous test data and leftover tissue samples for analysis. Exclusion Criteria: 1. Patients who are unable to provide sufficient tissue samples via surgery. 2. The investigator determines that the patient is not eligible for enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer (advanced stage) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China medical university hospital
Taichung, 40401, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New radiation method targets tough tumors
- New support program aims to ease emotional burden of advanced cancer
- Fasting during immunotherapy: a new way to boost treatment?
- Is a 1930s law blocking safe cancer info online? new survey investigates
- New survey aims to capture what really matters to cancer patients